Oxford, UK, April 7, 2008
PharmaVentures announced today that it had acted as an advisor and broker to PhotoBioChem, N.V. Holland for the sale of its patent assets to SpectraCure AB, Sweden.
Dr Fintan Walton, CEO, PharmaVentures said, “We were delighted to bring another successful outcome for one of our clients. We were proud to act as advisors and facilitators to PhotoBioChem in the divestment of its patent portfolio”.
PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporations.
- ends -